MRK Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

129.690

Open

128.770

VWAP

128.81

Vol

10.17M

Mkt Cap

318.26B

Low

127.885

Amount

1.31B

EV/EBITDA(TTM)

16.27

Total Shares

2.47B

356.59B

EV/OCF(TTM)

19.93

P/S(TTM)

4.80

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

Events Timeline

(ET)

2026-07-01

15:00:00

Merck Terminates MK-1167 Alzheimer's Study

2026-06-30 (ET)

2026-06-30

14:00:00

AWS Invests $1 Billion to Establish Forward Deployed Engineering Organization

2026-06-30

13:30:00

Anthropic Launches Claude Science for Scientific Research

2026-06-30

11:00:00

U.S. Lawmakers Investigate Merck and AbbVie Clinical Trials in China

2026-06-25 (ET)

2026-06-25

07:00:00

Merck's Keytruda Approved by FDA for Triple-Negative Breast Cancer

News

8.5

07-07Fool

iShares Core High Dividend ETF Outperforms S&P 500

8.5

07-07NASDAQ.COM

iShares Core High Dividend ETF Surges Over 15% Year-to-Date

4.5

07-06CNBC

Market Health Signals: Strong Performance in Healthcare and Agriculture Stocks

9.5

07-05Yahoo Finance

SCHD Delivers 227% Return Over 10 Years with Strong Cash Flow Stability

9.5

07-03NASDAQ.COM

Schwab U.S. Dividend ETF Shows Strong Performance

8.5

07-03Fool

The Potential and Returns of Dividend Investing

16 Analyst Rating

Wall Street analysts forecast MRK stock price to rise

11 Buy

5 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

95.00

Averages

119.53

High

139.00

Current: 0.000

Low

95.00

Averages

119.53

High

139.00

HSBC

Rajesh Kumar

Buy

maintain

$135 -> $150

AI Analysis

2026-07-06

New

Reason

HSBC

Rajesh Kumar

Price Target

$135 -> $150

AI Analysis

2026-07-06

New

maintain

Buy

Reason

HSBC analyst Rajesh Kumar raised the firm's price target on Merck to $150 from $135 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative outperformance potential for the second half of the year, noting that the Therapeutics space offering "attractive risk weighted returns," Tools "might be the best way to play a cyclical rally," and that MedTech is "cheap."

BofA

Buy

maintain

$130 -> $141

2026-06-30

Reason

BofA

Price Target

$130 -> $141

2026-06-30

maintain

Buy

Reason

BofA raised the firm's price target on Merck to $141 from $130 and keeps a Buy rating on the shares, citing a sector re-rating for the firm's raised target. The Phase 3 OptiTrop-Lung06 trial is a China-only trial run by Merck's partner and the data are unlikely to support approval in developed markets, but they should inform if SAC-TMT has the potential to be a foundational lung cancer drug, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MRK

Unlock Now

Valuation Metrics

The current forward P/E ratio for Merck & Co Inc (MRK.N) is 25.58, compared to its 5-year average forward P/E of 17.14. For a more detailed relative valuation and DCF analysis to assess Merck & Co Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

17.14

Current PE

25.58

Overvalued PE

32.07

Undervalued PE

2.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.49

Current EV/EBITDA

10.73

Overvalued EV/EBITDA

16.54

Undervalued EV/EBITDA

6.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.07

Current PS

4.47

Overvalued PS

4.66

Undervalued PS

3.48

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best quantum computer companies

Intellectia · 868 candidates

Market Cap Category: small, mid, large, megaAnalyst Consensus: Strong Buy, Moderate BuyRelative Vol: >= 1.50Target Price Upside Potential: AbovePrice, MoreAbovePriceMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Optionable: True

Ticker

Name

Market Cap$

NVDA

NVIDIA Corp

5.10T

AAPL

Apple Inc

4.38T

AVGO

Broadcom Inc

1.96T

WMT

Walmart Inc

932.53B

JPM

JPMorgan Chase & Co

871.43B

Visa Inc

619.95B

give me us30 biggest movers by market cap

Intellectia · 29 candidates

Region: USIs Index Component: DJI

Ticker

Name

Market Cap$

NVDA

NVIDIA Corp

5.14T

AAPL

Apple Inc

4.35T

MSFT

Microsoft Corp

2.97T

AMZN

Amazon.com Inc

2.65T

WMT

Walmart Inc

961.50B

JPM

JPMorgan Chase & Co

855.84B

Us30 companies and their performance

Intellectia · 29 candidates

Region: USIs Index Component: DJI

Ticker

Name

Market Cap$

NVDA

NVIDIA Corp

4.97T

AAPL

Apple Inc

4.28T

MSFT

Microsoft Corp

2.90T

AMZN

Amazon.com Inc

2.57T

WMT

Walmart Inc

963.25B

JPM

JPMorgan Chase & Co

859.37B

Elite pharma

Intellectia · 9 candidates

Sector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchIndustry: Biotechnology & Medical Research, PharmaceuticalsPrice: >= $-100.00Volume: >= -100Themes: Medical Instruments & Supplies, Genomics, Cancer Research, BiotechRsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Ema 20: >= -100Ema 60: >= -100Weekly Average Dollar Volume: >= -100

Ticker

Name

Market Cap$

JNJ

Johnson & Johnson

570.51B

ABBV

AbbVie Inc

398.27B

MRK

Merck & Co Inc

295.39B

AMGN

Amgen Inc

185.96B

VRTX

Vertex Pharmaceuticals Inc

113.14B

BIIB

Biogen Inc

29.39B

Mega Cap Stocks Bullish for a Month

Intellectia · 22 candidates

Market Cap Category: megaMoving Average Relationship: PriceAboveMA20One Month Rise Prob: >= 50One Month Predict Return: >= 0.0%Macd: bullish

Ticker

Name

Market Cap$

Micron Technology Inc

1.22T

CSCO

Cisco Systems Inc

498.59B

IBM

International Business Machines Corp

287.26B

AMD

Advanced Micro Devices Inc

884.63B

ORCL

Oracle Corp

662.44B

KLAC

KLA Corp

277.60B

xene swing trade

Intellectia · 61 candidates

Sector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, PharmaceuticalsRsi Category: moderateRelative Vol: >= 1.20List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA60Is Optionable: TrueSupport Resistance Relationship: PriceBreakResistance, PriceAroundResistance

Ticker

Name

Market Cap$

AVBP

ArriVent BioPharma Inc

1.41B

SCLX

Scilex Holding Co

75.57M

MGTX

MeiraGTx Holdings PLC

986.29M

TEVA

Teva Pharmaceutical Industries Limited..

41.13B

GILD

Gilead Sciences, Inc

166.90B

RVMD

Revolution Medicines Inc

33.48B

which megacap surged max yesterday

Intellectia · 64 candidates

Region: USMarket Cap Category: mega

Ticker

Name

Market Cap$

UNH

UnitedHealth Group Inc

359.98B

Philip Morris International Inc

291.34B

NFLX

Netflix Inc

369.12B

ABBV

AbbVie Inc

367.25B

LLY

Eli Lilly and Co

932.20B

COST

Costco Wholesale Corp

453.36B

Featured Screeners

Intellectia · 85 candidates

Market Cap: >= 30.00BList Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPCMonthly Average Dollar Volume: >= 3,000,000

Ticker

Name

Market Cap$

NVDA

NVIDIA Corp

5.06T

GOOG

Alphabet Inc

4.14T

AAPL

Apple Inc

3.98T

AMZN

Amazon.com Inc

2.84T

AVGO

Broadcom Inc

2.00T

WMT

Walmart Inc

1.04T

yes stocks

Intellectia · 27 candidates

Market Cap: >= 50.00BDividend Yield Ttm: 2.50 - 6Analyst Consensus: Strong Buy, Moderate BuyBeta: LowRiskRevenue 5yr Cagr: >= 7

Ticker

Name

Market Cap$

XOM

Exxon Mobil Corp

618.95B

CVX

Chevron Corp

368.92B

Coca-Cola Co

329.83B

UNH

UnitedHealth Group Inc

322.34B

MRK

Merck & Co Inc

276.38B

Philip Morris International Inc

255.91B

best left to buy now

Intellectia · 85 candidates

Analyst Consensus: Strong Buy, Moderate BuyEps 5yr Cagr: >= 5Pe Ttm: 8 - 35Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX

Ticker

Name

Market Cap$

GOOG

Alphabet Inc

4.14T

AAPL

Apple Inc

3.98T

JPM

JPMorgan Chase & Co

826.87B

Micron Technology Inc

560.17B

JNJ

Johnson & Johnson

547.64B

BAC

Bank of America Corp

371.11B

Whales Holding MRK

Pallas Capital Advisors LLC

Caxton Associates (USA) LLC

Applied Finance Advisors, LLC

Epoch Investment Partners, Inc.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Merck & Co Inc (MRK) stock price today?

The current price of MRK is 128.86 USD — it has increased 1.64

What is Merck & Co Inc (MRK)'s business?

What is the price predicton of MRK Stock?

Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is119.53 USD with a low forecast of 95.00 USD and a high forecast of 139.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.